A股申购 | 建发致新(301584.SZ)开启申购 为全国超过3300家医疗机构提供医疗器械直销服务

Core Viewpoint - The company, Jianfa Zhixin, is a national high-value medical device distributor that has initiated its IPO with a price of 7.05 yuan per share and a price-to-earnings ratio of 13.29 times, under the sponsorship of CITIC Securities [1] Company Overview - Jianfa Zhixin primarily engages in direct sales and distribution of medical devices, providing centralized operation services for medical consumables (SPD) to hospitals across China [1] - The company plays a crucial role in the medical device supply chain, linking manufacturers, distributors, and end medical institutions [1] - It offers direct sales services to over 3,300 medical institutions across 31 provinces, municipalities, and autonomous regions in China, with a wide range of products [1] - The company has established long-term partnerships with over 100 well-known domestic and international medical device manufacturers [1] Industry Trends - The medical device distribution industry is evolving towards channel integration and flattening due to policies like centralized procurement and the "two-invoice system" [2] - The company is leveraging the characteristics of high-value medical devices to enhance information management in traditional distribution operations [2] - The use of modern technologies such as information technology and IoT is aimed at reducing manual dependency, optimizing operational efficiency, and lowering costs [2] Financial Performance - The company reported revenues of approximately 11.882 billion yuan, 15.443 billion yuan, and 17.923 billion yuan for the years 2022, 2023, and 2024, respectively [3] - Net profits for the same years were approximately 189 million yuan, 227 million yuan, and 274 million yuan [3] - Total assets as of December 31 for 2022, 2023, and 2024 were approximately 90.57 billion yuan, 111.71 billion yuan, and 131.12 billion yuan, respectively [3] - The company's asset-liability ratio increased from 73.92% in 2022 to 79.32% in 2024 [3]